{"protocolSection":{"identificationModule":{"nctId":"NCT04181788","orgStudyIdInfo":{"id":"B8011007"},"secondaryIdInfos":[{"id":"2019-003818-14","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","officialTitle":"A Phase 1b/2 Open-Label Study to Evaluate Pharmacokinetics, Safety, Efficacy, and Pharmacodynamics of PF-06801591 (PD-1 Inhibitor) in Participants With Advanced Malignancies"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-03-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-03-03","type":"ACTUAL"},"completionDateStruct":{"date":"2026-06-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-11-14","studyFirstSubmitQcDate":"2019-11-27","studyFirstPostDateStruct":{"date":"2019-11-29","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-02-28","resultsFirstSubmitQcDate":"2023-04-14","resultsFirstPostDateStruct":{"date":"2023-05-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-20","lastUpdatePostDateStruct":{"date":"2025-06-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.\n\nThis study consists of 2 parts:\n\nPhase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients."},"conditionsModule":{"conditions":["Advanced Malignancies","Non-small-cell Lung Cancer"],"keywords":["Advanced solid tumors","NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":155,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A1 (Phase 1b)","type":"EXPERIMENTAL","interventionNames":["Drug: PF-06801591"]},{"label":"Arm B1 (Phase 1b)","type":"EXPERIMENTAL","interventionNames":["Drug: PF-06801591"]},{"label":"Arm A2 (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Drug: PF-06801591"]},{"label":"Arm B2 (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Drug: PF-06801591"]}],"interventions":[{"type":"DRUG","name":"PF-06801591","description":"A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.","armGroupLabels":["Arm A1 (Phase 1b)","Arm A2 (Phase 2)","Arm B1 (Phase 1b)","Arm B2 (Phase 2)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2).\n\nFor the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.","timeFrame":"Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms"},{"measure":"Phase 2: AUCτ of PF-06801591 at Steady State","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nAUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)","timeFrame":"Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm"},{"measure":"Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nSteady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)","timeFrame":"Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm"}],"secondaryOutcomes":[{"measure":"Number of Participants With Treatment-Emergent Adverse Events","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nAn AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.","timeFrame":"Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day)."},{"measure":"Number of Participants With Laboratory Abnormalities","description":"Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.","timeFrame":"Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day)."},{"measure":"Pharmacokinetic Parameters: AUCτ After First Dose","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nAUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)","timeFrame":"Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Cycle 1 Day 1, 8, 15, 22, Cycle 2 Day 1; for the PF-06801591 600 mg SC Q6W arms, Cycle 1 Day 1, 8, 15, 29, Cycle 2 Day 1"},{"measure":"Pharmacokinetic Parameters: Ctrough After First Dose","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nCtrough is pre-dose concentration after single dose (first dose).","timeFrame":"Phase 1b/2: Cycle 2 Day 1 for all Arms"},{"measure":"Pharmacokinetic Parameters: Ctrough at Steady State","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nSteady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)","timeFrame":"Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Day 1 of Cycle 4; for the PF-06801591 600 mg SC Q6W arms, Day 1 of Cycle 3"},{"measure":"Number of Participants With Treatment-Induced Anti-Drug Antibody (ADA) /Neutralizing Antibodies (NAb)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nTreatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09).\n\nTreatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.","timeFrame":"Phase 1b/2: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10 and end of treatment (EOT) for the PF-06801591 300 mg SC Q4W arms; Day 1 of Cycle 1, 2, 3, 4, 5, 7 and EOT for the PF-06801591 600 mg SC Q6W arms"},{"measure":"Number of Participants With Objective Response (OR)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nOR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1.\n\nComplete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10 mm). All target lesions must be assessed.\n\nPartial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.","timeFrame":"Phase 1b/2: Up to 30 months"},{"measure":"Time to Response (TTR)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nTTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.","timeFrame":"Phase 1b/2: Up to 30 months"},{"measure":"Number of Participants With Objective Response (Complete Response + Partial Response) Reported by Baseline Programmed Death-Ligand 1 (PD-L1) Status (High, Low, and Unknown)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nOR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10 mm). All target lesions must be assessed.\n\nPR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.\n\nPD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.","timeFrame":"Phase 1b/2: Baseline up to 30 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years (≥ 20 years in Japan; ≥ 19 years in South Korea)\n* Easter Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate bone marrow function, renal and liver functions Phase 1b\n* Histological or Cytological diagnosis of advanced solid tumor with clinical evidence of response to anti-PD-1 or PD-L1 agent\n* Participant must have received at least 1 prior line of therapy for recurrent or metastatic disease, and must have progressed/relapsed, be refractory, or intolerant to standard therapy approved for the specific tumor type Phase 2\n* Participants must have a documented diagnosis of stage III where participants are not candidates for surgical resection or definitive chemoradiation, or stage IV NSCLC\n* EGFR mutation, BRAF mutation, and ALK or ROS1 translocation/rearrangement are not permitted\n* Participants whose tumor is known to be PD-L1 positive (Tumor Proportion Score \\[TPS\\] ≥1%) or unknown are eligible\n* Up to 1 line of prior therapy in advanced or metastatic disease settings allowed\n* Participant should not have received prior treatment with anti PD-1/PD-L1 drugs\n* At least one measurable lesion as defined by RECIST version 1.1\n\nExclusion Criteria:\n\n* Participants with known symptomatic brain metastases requiring steroids\n* Participants with Interstitial Lung Disease history or complication\n* Q-T interval corrected for heart rate QTc \\> 450 msec for male participants or QTc \\> 470 msec for female participants or QTc \\> 480 msec in participants with right bundle branch block.\n* Hypertension that cannot be controlled by medications (eg, systolic \\> 150 mmHg and diastolic \\> 90 mmHg) despite optimal medical therapy.\n* Known or suspected hypersensitivity to active ingredient or excipients of the study drug.\n* History of Grade ≥3 immune mediated AE (including AST/ ALT elevations that where considered drug related and cytokine release syndrome \\[CRS\\]) that was considered related to prior immune modulatory therapy (eg, immune checkpoint inhibitors, co-stimulatory agents, etc.) and required immunosuppressive therapy (For Phase 1b only).\n* Vaccination with live attenuated vaccines within 4 weeks prior to randomization is prohibited; however inactivated vaccines are permitted.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Beijing Cancer hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Chongqing Cancer Hospital","city":"Chongqing","state":"Chongqing Municipality","zip":"400030","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Nanjing Drum Tower Hospital","city":"Nanjing","state":"Jiangsu","zip":"210008","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Huashan Hospital Affiliated to Fudan University","city":"Shanghai","state":"Shanghai Municipality","zip":"201107","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"National Cancer Center Hospital","city":"Chuo-ku","state":"Tokyo","zip":"104-0045","country":"Japan"},{"facility":"Russian Research Centre for Radiology and Surgical Technologies","city":"Saint Petersburg","state":"Pesochny","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Private Medical Institution \"Euromedservice\"","city":"Pushkin","state":"Sankt-Peterburg","zip":"196603","country":"Russia","geoPoint":{"lat":59.71417,"lon":30.39642}},{"facility":"Klinika UZI 4D, LLC","city":"Pyatigorsk","state":"Stavropol Kray","zip":"357502","country":"Russia","geoPoint":{"lat":44.05,"lon":43.05036}},{"facility":"State budgetary institution of healthcare of Yaroslavl region \"Clinical oncology hospital\"","city":"Yaroslavl","state":"Yaroslavl Oblast","zip":"150054","country":"Russia","geoPoint":{"lat":57.62987,"lon":39.87368}},{"facility":"Evimed Llc","city":"Chelyabinsk","zip":"454048","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine","city":"Chelyabinsk","zip":"454087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"facility":"Ars Medika Center, LLC","city":"Kaliningrad","zip":"236006","country":"Russia","geoPoint":{"lat":54.70639,"lon":20.51102}},{"facility":"GBUZ Regional Clinical Hospital of Kaliningrad region","city":"Kaliningrad","country":"Russia","geoPoint":{"lat":54.70639,"lon":20.51102}},{"facility":"Enlimed Llc","city":"Kopeysk","zip":"456620","country":"Russia","geoPoint":{"lat":55.11686,"lon":61.61807}},{"facility":"Orenburg Regional Clinical Oncological Dispensary","city":"Orenburg","zip":"460021","country":"Russia","geoPoint":{"lat":51.76712,"lon":55.09883}},{"facility":"Russian Scientific Center For Radiology and Surgical Technologies","city":"Pesochny","zip":"197758","country":"Russia"},{"facility":"LLC Medical Center \"Magnit\"","city":"Saint Petersburg","zip":"190005","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Llc \"Mss\"","city":"Saint Petersburg","zip":"191025","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"North-West Medical Center","city":"Saint Petersburg","zip":"191119","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Road clinical clinic of JSC \"RZD\"","city":"Saint Petersburg","zip":"192007","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"NS HI \"Road Clinical Hospital of JSC \"Russian Railways\"\"","city":"Saint Petersburg","zip":"195271","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Private Healthcare Institution \"Clinical Hospital \"RZD-Medicine\" of St. Petersburg","city":"Saint Petersburg","zip":"195271","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"LLC \"Diagnostic center \"Energo\"","city":"Saint Petersburg","zip":"196247","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Medical University REAVIZ","city":"Samara","zip":"443001","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"Medical University REAVIZ","city":"Samara","zip":"443011","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam-si","state":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Gachon University Gil Medical Center","city":"Incheon","zip":"21656","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Severance Hospital, Yonsei Univ. Health System","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Kaohsiung Medical University Chung-Ho Memorial Hospital","city":"Kaohsiung City","zip":"807","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Limited Liability Company \"MedX-ray International Group\"","city":"Pliuty Village","state":"Kyiv Oblast","country":"Ukraine"},{"facility":"Asklepion Medical Center","city":"Khodosovka","state":"Kyivska Oblast","zip":"08173","country":"Ukraine","geoPoint":{"lat":50.271,"lon":30.52072}},{"facility":"\"Medeya Sumy\" LLC","city":"Sumy","state":"Sumska Oblast","zip":"40021","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council","city":"Dnipro","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Llc \"Mdc Expert\"","city":"Dnipro","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Municipal Non-profit Enterprise \"SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC\"","city":"Ivano-Frankivsk","zip":"76018","country":"Ukraine","geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"Private Enterprise of Private Manufacturing Company \"Acinus\", Medical and Diagnostic Center","city":"Kirovohrad","zip":"25006","country":"Ukraine","geoPoint":{"lat":48.50834,"lon":32.26618}},{"facility":"Medical centre \"Verum\" Limited Liability Company","city":"Kyiv","zip":"03039","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Vita Сom LLC","city":"Kyiv","zip":"03141","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"The State Institution \"Romodanov Neurosurgery Institute,","city":"Kyiv","zip":"04050","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Llc Medical Centre","city":"Odesa","zip":"65006","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"Municipal Non-profit Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council","city":"Odesa","zip":"65025","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"Llc Lidermed","city":"Odesa","zip":"65062","country":"Ukraine","geoPoint":{"lat":46.48572,"lon":30.74383}},{"facility":"Municipal Non Profit enterprise of Sumy Regional Council \"Sumy Regional Clinical Oncology Center\"","city":"Sumy","zip":"40022","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Llc Medical Center Diamed","city":"Uzhhorod","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"MNPE Central City Clinical Hospital of Uzhhorod City Council","city":"Uzhhorod","zip":"88000","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Мunicipal non-profit enterprise \"Zhytomyr Regional Oncology Dispensary\" of Zhytomyr Regional Council","city":"Zhytomyr","zip":"10002","country":"Ukraine","geoPoint":{"lat":50.26235,"lon":28.67913}}]},"referencesModule":{"references":[{"pmid":"39281971","type":"DERIVED","citation":"Penkov K, Bondarenko I, Saenko DV, Kulyaba Y, Guo J, Gong Y, Yamamoto N, Hotko YS, Boyko V, Fadeeva NV, Ursol GM, Ahn HK, Kislov NV, Shen CI, Davis C, Kowalski K, Michelon E, Pavlov D, Hirohashi T, Cho BC. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies. Ther Adv Med Oncol. 2024 Sep 11;16:17588359241274592. doi: 10.1177/17588359241274592. eCollection 2024."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=B8011007"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Phase 1b Escalation 300 mg SC Q4W","description":"PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9."},{"id":"FG001","title":"Phase 1b Expansion 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20."},{"id":"FG002","title":"Phase 1b Escalation 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9."},{"id":"FG003","title":"Phase 1b Expansion 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8."},{"id":"FG004","title":"Phase 2 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28."},{"id":"FG005","title":"Phase 2 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18."}],"periods":[{"title":"TREATMENT","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"41"},{"groupId":"FG005","numSubjects":"80"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"41"},{"groupId":"FG005","numSubjects":"80"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"8"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"20"},{"groupId":"FG005","numSubjects":"38"}]},{"type":"Global deterioration of health status","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"5"}]},{"type":"Other unspecified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"15"}]}]},{"title":"FOLLOW-UP","milestones":[{"type":"STARTED","comment":"All participants who entered treatment phase were either on-going on treatment or discontinued treatment. Those who discontinued treatment either entered the follow-up period or discontinued the study at the end of treatment.","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"20"},{"groupId":"FG005","numSubjects":"49"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"22"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"27"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"20"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Other unspecified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"3"}]},{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Phase 1b Escalation 300 mg SC Q4W","description":"PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9."},{"id":"BG001","title":"Phase 1b Expansion 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20."},{"id":"BG002","title":"Phase 1b Escalation 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9."},{"id":"BG003","title":"Phase 1b Expansion 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8."},{"id":"BG004","title":"Phase 2 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28."},{"id":"BG005","title":"Phase 2 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"41"},{"groupId":"BG005","value":"80"},{"groupId":"BG006","value":"155"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.0","spread":"13.29"},{"groupId":"BG001","value":"57.3","spread":"15.78"},{"groupId":"BG002","value":"62.7","spread":"10.33"},{"groupId":"BG003","value":"62.4","spread":"10.02"},{"groupId":"BG004","value":"63.9","spread":"11.75"},{"groupId":"BG005","value":"62.9","spread":"10.62"},{"groupId":"BG006","value":"62.6","spread":"11.33"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"48"},{"groupId":"BG006","value":"85"}]}]},{"title":"65 - <75 years","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"49"}]}]},{"title":"75 - <85 years","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"19"}]}]},{"title":"≥85 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"39"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"32"},{"groupId":"BG005","value":"66"},{"groupId":"BG006","value":"116"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"41"},{"groupId":"BG005","value":"80"},{"groupId":"BG006","value":"155"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"34"},{"groupId":"BG005","value":"62"},{"groupId":"BG006","value":"96"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"18"},{"groupId":"BG006","value":"59"}]}]},{"title":"Multiracial","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]},{"title":"Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2).\n\nFor the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.","populationDescription":"DLT-evaluable analysis set included all participants who received at least 1 dose of study treatment in the Phase 1b and either experienced DLT during the DLT-evaluation period or completed the DLT-evaluation period without DLT.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms","groups":[{"id":"OG000","title":"Phase 1b Escalation 300 mg SC Q4W","description":"PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9."},{"id":"OG001","title":"Phase 1b Expansion 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20."},{"id":"OG002","title":"Phase 1b Escalation 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9."},{"id":"OG003","title":"Phase 1b Expansion 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Phase 2: AUCτ of PF-06801591 at Steady State","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nAUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)","populationDescription":"Phase 2: The PK concentration analysis set was a subset of the safety analysis set and included participants who had at least 1 reportable concentration measurement. Safety analysis set included all enrolled participants who received at least 1 dose of study drug. Here \"Number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram*hour per milliliter (μg*hr/mL)","timeFrame":"Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm","groups":[{"id":"OG000","title":"Phase 2 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28."},{"id":"OG001","title":"Phase 2 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"49"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20800","spread":"54"},{"groupId":"OG001","value":"48090","spread":"47"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Phase 2 600 mg SC Q6W (experimental) vs. Phase 2 300 mg SC Q4W (control)","nonInferiorityType":"OTHER","nonInferiorityComment":"Ratio of experimental vs control","paramType":"Ratio of experimental vs control","paramValue":"231.20","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"190.09","ciUpperLimit":"281.21"}]},{"type":"PRIMARY","title":"Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nSteady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)","populationDescription":"Phase 2: The PK concentration analysis set was a subset of the safety analysis set and included participants who had at least 1 reportable concentration measurement. Safety analysis set included all enrolled participants who received at least 1 dose of study drug. Here \"Number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram per milliliter (μg/mL)","timeFrame":"Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm","groups":[{"id":"OG000","title":"Phase 2 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28."},{"id":"OG001","title":"Phase 2 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"55"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.48","spread":"60"},{"groupId":"OG001","value":"23.95","spread":"74"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Phase 2 600 mg SC Q6W (experimental) vs. Phase 2 300 mg SC Q4W (control)","nonInferiorityType":"OTHER","nonInferiorityComment":"Ratio of experimental vs control","paramType":"Ratio of experimental vs control","paramValue":"111.48","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"86.31","ciUpperLimit":"143.99"}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nAn AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants With Laboratory Abnormalities","description":"Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: AUCτ After First Dose","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nAUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Cycle 1 Day 1, 8, 15, 22, Cycle 2 Day 1; for the PF-06801591 600 mg SC Q6W arms, Cycle 1 Day 1, 8, 15, 29, Cycle 2 Day 1","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: Ctrough After First Dose","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nCtrough is pre-dose concentration after single dose (first dose).","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: Cycle 2 Day 1 for all Arms","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Pharmacokinetic Parameters: Ctrough at Steady State","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nSteady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Day 1 of Cycle 4; for the PF-06801591 600 mg SC Q6W arms, Day 1 of Cycle 3","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants With Treatment-Induced Anti-Drug Antibody (ADA) /Neutralizing Antibodies (NAb)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nTreatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09).\n\nTreatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10 and end of treatment (EOT) for the PF-06801591 300 mg SC Q4W arms; Day 1 of Cycle 1, 2, 3, 4, 5, 7 and EOT for the PF-06801591 600 mg SC Q6W arms","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants With Objective Response (OR)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nOR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1.\n\nComplete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10 mm). All target lesions must be assessed.\n\nPartial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: Up to 30 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Time to Response (TTR)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nTTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: Up to 30 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Number of Participants With Objective Response (Complete Response + Partial Response) Reported by Baseline Programmed Death-Ligand 1 (PD-L1) Status (High, Low, and Unknown)","description":"This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2).\n\nOR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \\<10 mm). All target lesions must be assessed.\n\nPR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.\n\nPD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2025-12","timeFrame":"Phase 1b/2: Baseline up to 30 months","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality.","description":"Same event may appear as both an adverse event (AE) and serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event.","eventGroups":[{"id":"EG000","title":"Phase 1b Escalation 300 mg SC Q4W","description":"PF-06801591 300 mg was given subcutaneously (SC) every 4 weeks (Q4W) (Cycles are 28 days in length). The maximum number of cycles was 9.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":1,"seriousNumAtRisk":4,"otherNumAffected":4,"otherNumAtRisk":4},{"id":"EG001","title":"Phase 1b Expansion 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 20.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":2,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG002","title":"Phase 1b Escalation 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC every 6 weeks (Q6W) (Cycles are 42 days in length). The maximum number of cycles was 9.","deathsNumAffected":1,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG003","title":"Phase 1b Expansion 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 8.","deathsNumAffected":2,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12},{"id":"EG004","title":"Phase 2 300 mg SC Q4W","description":"PF-06801591 300 mg was given SC Q4W (Cycles are 28 days in length). The maximum number of cycles was 28.","deathsNumAffected":16,"deathsNumAtRisk":41,"seriousNumAffected":16,"seriousNumAtRisk":41,"otherNumAffected":40,"otherNumAtRisk":41},{"id":"EG005","title":"Phase 2 600 mg SC Q6W","description":"PF-06801591 600 mg was given SC Q6W (Cycles are 42 days in length). The maximum number of cycles was 18.","deathsNumAffected":31,"deathsNumAtRisk":80,"seriousNumAffected":13,"seriousNumAtRisk":80,"otherNumAffected":58,"otherNumAtRisk":80}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Inappropriate antidiuretic","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":6,"numAtRisk":12},{"groupId":"EG004","numAffected":8,"numAtRisk":41},{"groupId":"EG005","numAffected":10,"numAtRisk":80}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":5,"numAtRisk":80}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":9,"numAtRisk":41},{"groupId":"EG005","numAffected":6,"numAtRisk":80}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":4,"numAtRisk":80}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":5,"numAtRisk":80}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":41},{"groupId":"EG005","numAffected":6,"numAtRisk":80}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Blood corticotrophin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood corticotrophin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Blood glucose decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":4,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood thyroid stimulating hormone decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Cortisol decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Free thyroxine index increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":5,"numAtRisk":80}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Red blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Thyroid hormones decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Total bile acids increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":8,"numAtRisk":41},{"groupId":"EG005","numAffected":10,"numAtRisk":80}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":8,"numAtRisk":41},{"groupId":"EG005","numAffected":8,"numAtRisk":80}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Hypermagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hyperphosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":41},{"groupId":"EG005","numAffected":5,"numAtRisk":80}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Gouty arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":2,"numAtRisk":80}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":1,"numAtRisk":80}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":3,"numAtRisk":41},{"groupId":"EG005","numAffected":7,"numAtRisk":80}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":2,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":6,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":9,"numAtRisk":41},{"groupId":"EG005","numAffected":11,"numAtRisk":80}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":4,"numAtRisk":41},{"groupId":"EG005","numAffected":3,"numAtRisk":80}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":5,"numAtRisk":41},{"groupId":"EG005","numAffected":4,"numAtRisk":80}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":4},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":6,"numAtRisk":80}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":3,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":4,"numAtRisk":80}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":1,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Skin hypopigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]},{"term":"Vitiligo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v25.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":4},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":12},{"groupId":"EG004","numAffected":0,"numAtRisk":41},{"groupId":"EG005","numAffected":0,"numAtRisk":80}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-06-24","uploadDate":"2023-02-28T09:45","filename":"Prot_000.pdf","size":6444443},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-04-07","uploadDate":"2023-02-28T09:45","filename":"SAP_001.pdf","size":953474}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-03-27","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}